Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-DXP593 in mild-to-moderate COVID-19
NCT04551898Phase 2Completed
- Sponsor
- BeiGene
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of BGB-DXP593 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by BeiGene. Primary endpoint: Change From Baseline to Day 8 in SARS-CoV-2 Viral Shedding. Started Dec 2020; status: completed.
02
Drugs
BGB-DXP593
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04551898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551898.